The acquisition provides AB Sciex with an entry into the liquid chromatography market through the ability to provide instrumentation and consumables used to separate, identify and quantify small quantities of molecules based on their chemical properties and to couple them with mass spectrometry instruments to form complete workflow solutions.

The technologies which AB Sciex is acquiring are NanoLC-Ultra System for proteomics, the cHiPLC-nanoflex System for protein peptide separations, and the ExpressHT-Ultra HPLC System for LC/MS studies of pharmacokinetics and drug metabolism.

Andy Boorn, president of AB Sciex, said: “The acquisition demonstrates the strategy for growth that resulted in the creation of AB Sciex. Eksigent’s portfolio of HPLC technologies is among the innovative within the industry and is complementary to our market-leading mass spectrometry systems. We expect to further develop and broaden the use of these technologies for a variety of life science applications.”

Laura Lauman, president, said: “AB Sciex is focused on providing some of the technologies and integrated workflow solutions for the life science industry. This acquisition addresses a broad range of applications, such as the growing peptide quantitation market, by further enabling breakthrough performance and ease of use through the combination of Eksigent’s liquid chromatography technology and AB Sciex ’s mass spectrometers.

“The use of liquid chromatography continues to grow, and we are looking forward to work with the Eksigent team to create additional value for our customers around the world.”